Bruno Giros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/419744/publications.pdf

Version: 2024-02-01

206 papers 24,409 citations

70 h-index 152 g-index

237 all docs

 $\begin{array}{c} 237 \\ \text{docs citations} \end{array}$

times ranked

237

19893 citing authors

#	Article	IF	CITATIONS
1	The Orphan GPCR Receptor, GPR88, Interacts with Nuclear Protein Partners in the Cerebral Cortex. Cerebral Cortex, 2022, 32, 479-489.	1.6	1
2	Mice with dopaminergic neuron-specific deletion of DTNBP-1 gene show blunted nucleus accumbens dopamine release and associated behaviors. Neuropharmacology, 2021, 184, 108440.	2.0	1
3	Regulation of GluA1 phosphorylation by d â€amphetamine and methylphenidate in the cerebellum. Addiction Biology, 2021, 26, e12995.	1.4	2
4	Dysfunction of homeostatic control of dopamine by astrocytes in the developing prefrontal cortex leads to cognitive impairments. Molecular Psychiatry, 2020, 25, 732-749.	4.1	71
5	Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression. Molecular Psychiatry, 2020, 25, 1245-1259.	4.1	24
6	LSP5-2157 a new inhibitor of vesicular glutamate transporters. Neuropharmacology, 2020, 164, 107902.	2.0	7
7	Noradrenergic System Variability in Resilience Against Stress. Biological Psychiatry, 2020, 87, S131.	0.7	O
8	GPR56/ADGRG1 is associated with response to antidepressant treatment. Nature Communications, 2020, 11, 1635.	5.8	38
9	Early reduced dopaminergic tone mediated by D3 receptor and dopamine transporter in absence epileptogenesis. Epilepsia, 2019, 60, 2128-2140.	2.6	8
10	Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. PLoS Genetics, 2019, 15, e1008352.	1.5	62
11	Cartography of hevin-expressing cells in the adult brain reveals prominent expression in astrocytes and parvalbumin neurons. Brain Structure and Function, 2019, 224, 1219-1244.	1.2	20
12	Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration. Scientific Reports, 2019, 9, 7850.	1.6	14
13	The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia. Neuropharmacology, 2019, 146, 74-83.	2.0	36
14	The NeuroD6 Subtype of VTA Neurons Contributes to Psychostimulant Sensitization and Behavioral Reinforcement. ENeuro, 2019, 6, ENEURO.0066-19.2019.	0.9	34
15	Regional brain volume changes following chronic antipsychotic administration are mediated by the dopamine D2 receptor. NeuroImage, 2018, 176, 226-238.	2.1	29
16	Cocaine increases dopaminergic connectivity in the nucleus accumbens. Brain Structure and Function, 2018, 223, 913-923.	1.2	20
17	Structural and Functional Characterization of the Interaction of Snapin with the Dopamine Transporter: Differential Modulation of Psychostimulant Actions. Neuropsychopharmacology, 2018, 43, 1041-1051.	2.8	7
18	Antidepressive effects of targeting ELK-1 signal transduction. Nature Medicine, 2018, 24, 591-597.	15.2	33

#	Article	IF	CITATIONS
19	Deleting IGF-1 receptor from forebrain neurons confers neuroprotection during stroke and upregulates endocrine somatotropin. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 396-412.	2.4	38
20	109. From Early Life Adversity to Adolescence Depression: White Matter Remodelling in a Translational Animal Model. Biological Psychiatry, 2017, 81, S46.	0.7	0
21	Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity. Toxicology, 2017, 375, 48-57.	2.0	92
22	Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice. Scientific Reports, 2017, 7, 12432.	1.6	15
23	695. Resilience against Chronic Stress is Mediated by Noradrenergic Regulation of the Ventral Tegmental Area. Biological Psychiatry, 2017, 81, S282.	0.7	0
24	Disrupted hippocampal neuregulin-1/ErbB3 signaling and dentate gyrus granule cell alterations in suicide. Translational Psychiatry, 2017, 7, e1161-e1161.	2.4	22
25	Regulation of the Hippocampal Network by VGLUT3-Positive CCK- GABAergic Basket Cells. Frontiers in Cellular Neuroscience, 2017, 11, 140.	1.8	48
26	VMAT2-Mediated Neurotransmission from Midbrain Leptin Receptor Neurons in Feeding Regulation. ENeuro, 2017, 4, ENEURO.0083-17.2017.	0.9	15
27	Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour. Journal of Psychiatry and Neuroscience, 2016, 41, 169-181.	1.4	21
28	GABAB receptor cell-surface export is controlled by an endoplasmic reticulum gatekeeper. Molecular Psychiatry, 2016, 21, 480-490.	4.1	45
29	Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons. Nature Neuroscience, 2016, 19, 560-563.	7.1	130
30	Genetic and functional analyses demonstrate a role for abnormal glycinergic signaling in autism. Molecular Psychiatry, 2016, 21, 936-945.	4.1	85
31	Vulnerability to opiate intake in maternally deprived rats: implication of MeCP2 and of histone acetylation. Addiction Biology, 2015, 20, 120-131.	1.4	21
32	The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. Molecular Psychiatry, 2015, 20, 1448-1459.	4.1	59
33	Ctr9, a Protein in the Transcription Complex Paf1, Regulates Dopamine Transporter Activity at the Plasma Membrane. Journal of Biological Chemistry, 2015, 290, 17848-17862.	1.6	11
34	Highly delayed systemic translocation of aluminum-based adjuvant in CD1 mice following intramuscular injections. Journal of Inorganic Biochemistry, 2015, 152, 199-205.	1.5	41
35	Modulation of Hippocampus-Prefrontal Cortex Synaptic Transmission and Disruption of Executive Cognitive Functions by MK-801. Cerebral Cortex, 2015, 25, 1348-1361.	1.6	49
36	Presynaptic D2 Dopamine Receptors Control Long-Term Depression Expression and Memory Processes in the Temporal Hippocampus. Biological Psychiatry, 2015, 77, 513-525.	0.7	84

#	Article	IF	Citations
37	Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3 \hat{l}^2 signaling. Molecular Psychiatry, 2015, 20, 889-900.	4.1	54
38	Inhibition of Dopamine Transporter Activity Impairs Synaptic Depression in Rat Prefrontal Cortex Through Over-Stimulation of D1 Receptors. Cerebral Cortex, 2014, 24, 945-955.	1.6	24
39	Morphometric characterization of microglial phenotypes in human cerebral cortex. Journal of Neuroinflammation, 2014, 11, 12.	3.1	258
40	A highly tunable dopaminergic oscillator generates ultradian rhythms of behavioral arousal. ELife, 2014, 3, .	2.8	141
41	The dopamine D1 receptor agonist SKF 38393 improves temporal order memory performance in maternally deprived rats. Neurobiology of Learning and Memory, 2013, 106, 268-273.	1.0	30
42	In Vivo Occupancy of Dopamine D ₃ Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficitâ€"Hyperactivity Disorder. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 501-510.	1.3	28
43	Postnatal Growth Defects in Mice with Constitutive Depletion of Central Serotonin. ACS Chemical Neuroscience, 2013, 4, 171-181.	1.7	71
44	Possible involvement of endocannabinoids in the increase of morphine consumption in maternally deprived rat. Neuropharmacology, 2013, 65, 193-199.	2.0	18
45	Paradoxical increase in survival of newborn neurons in the dentate gyrus of mice with constitutive depletion of serotonin. European Journal of Neuroscience, 2013, 38, 2650-2658.	1.2	38
46	dcc orchestrates the development of the prefrontal cortex during adolescence and is altered in psychiatric patients. Translational Psychiatry, 2013, 3, e338-e338.	2.4	83
47	Doublecortin Knockout Mice Show Normal Hippocampal-Dependent Memory Despite CA3 Lamination Defects. PLoS ONE, 2013, 8, e74992.	1.1	18
48	Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Molecular Psychiatry, 2012, 17, 926-939.	4.1	125
49	l-DOPA Impairs Proteasome Activity in Parkinsonism through D ₁ Dopamine Receptor. Journal of Neuroscience, 2012, 32, 681-691.	1.7	37
50	S.12.04 Regulation of â€~non-glutamatergic' transmission by the vesicular glutamate transporter VGLUT3. European Neuropsychopharmacology, 2012, 22, S129.	0.3	0
51	P.6.b.002 Compulsive-impulsive alcohol consumption in serotonin deficient vesicular monoamine transporter 2 (Vmat2) knockout mice. European Neuropsychopharmacology, 2012, 22, S395.	0.3	0
52	Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 1017-1023.	1.4	43
53	Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 36-50.	2.5	52
54	Both chronic treatments by epothilone D and fluoxetine increase the shortâ€term memory and differentially alter the mood status of <scp>STOP</scp> / <scp>MAP</scp> 6 <scp>KO</scp> mice. Journal of Neurochemistry, 2012, 123, 982-996.	2.1	30

#	Article	IF	Citations
55	Maternal deprivation induces deficits in temporal memory and cognitive flexibility and exaggerates synaptic plasticity in the rat medial prefrontal cortex. Neurobiology of Learning and Memory, 2012, 98, 207-214.	1.0	70
56	Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: Effects of fluoxetine and MK-801. Neuropharmacology, 2012, 62, 503-517.	2.0	47
57	The deletion of STOP/MAP6 protein in mice triggers highly altered mood and impaired cognitive performances. Journal of Neurochemistry, 2012, 121, 99-114.	2.1	35
58	Early stress leads to effects on estrous cycle and differential responses to stress. Physiology and Behavior, 2011, 102, 304-310.	1.0	14
59	Maternal high-fat intake alters presynaptic regulation of dopamine in the nucleus accumbens and increases motivation for fat rewards in the offspring. Neuroscience, 2011, 176, 225-236.	1.1	101
60	Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain, 2011, 134, 2321-2338.	3.7	29
61	Severe Serotonin Depletion after Conditional Deletion of the Vesicular Monoamine Transporter 2 Gene in Serotonin Neurons: Neural and Behavioral Consequences. Neuropsychopharmacology, 2011, 36, 2538-2550.	2.8	71
62	Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. International Journal of Neuropsychopharmacology, 2010, 13, 1207-1218.	1.0	80
63	Evidence of long-term expression of behavioral sensitization to both cocaine and ethanol in dopamine transporter knockout mice. Psychopharmacology, 2010, 208, 57-66.	1.5	28
64	Rose Bengal analogs and vesicular glutamate transporters (VGLUTs). Bioorganic and Medicinal Chemistry, 2010, 18, 6922-6933.	1.4	26
65	Inhibitory and facilitory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: A comparison to human $\hat{l}\pm 1$ - and $\hat{l}\pm 2$ -adrenoceptor subtypes. European Journal of Pharmacology, 2010, 634, 1-9.	1.7	20
66	The deletion of the microtubuleâ€associated STOP protein affects the serotonergic mouse brain network. Journal of Neurochemistry, 2010, 115, 1579-1594.	2.1	27
67	Zebrafish atlastin controls motility and spinal motor axon architecture via inhibition of the BMP pathway. Nature Neuroscience, 2010, 13, 1380-1387.	7.1	106
68	VGLUT3 (Vesicular Glutamate Transporter Type 3) Contribution to the Regulation of Serotonergic Transmission and Anxiety. Journal of Neuroscience, 2010, 30, 2198-2210.	1.7	159
69	THE EFFECT OF NON-COMPETITIVE NMDA RECEPTOR ANTAGONIST MK801 ON HIPPOCAMPUS-PREFRONTAL CORTEX SYNAPTIC RESPONSES AND EXECUTIVE COGNITIVE FUNCTION IN RATS. Schizophrenia Research, 2010, 117, 393.	1.1	O
70	Maternal deprivation induces depressive-like behaviours only in female rats. Behavioural Brain Research, 2010, 213, 278-287.	1.2	45
71	Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats. Neuropsychopharmacology, 2009, 34, 2469-2476.	2.8	36
72	Increased Dopamine Transmission Impairs Behavioral Flexibility and Synaptic Plasticity. European Psychiatry, 2009, 24, .	0.1	0

#	Article	IF	CITATIONS
73	Impairment of SLC17A8 Encoding Vesicular Glutamate Transporter-3, VGLUT3, Underlies Nonsyndromic Deafness DFNA25 and Inner Hair Cell Dysfunction in Null Mice. American Journal of Human Genetics, 2008, 83, 278-292.	2.6	237
74	The vesicular glutamate transporter VGLUT3 synergizes striatal acetylcholine tone. Nature Neuroscience, 2008, 11, 292-300.	7.1	181
75	Altered aminergic neurotransmission in the brain of organic cation transporter 3â€deficient mice. Journal of Neurochemistry, 2008, 106, 1471-1482.	2.1	99
76	Chronic valproate normalizes behavior in mice overexpressing calcineurin. European Journal of Pharmacology, 2008, 580, 153-160.	1.7	6
77	Association between the PPP3CC gene, coding for the calcineurin gamma catalytic subunit, and bipolar disorder. Behavioral and Brain Functions, 2008, 4, 2.	1.4	27
78	Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiology of Aging, 2008, 29, 1619-1630.	1.5	136
79	Antipsychotics increase vesicular glutamate transporter 2 (VGLUT2) expression in thalamolimbic pathways. Neuropharmacology, 2008, 54, 497-508.	2.0	32
80	Epilepsy in Dcx Knockout Mice Associated with Discrete Lamination Defects and Enhanced Excitability in the Hippocampus. PLoS ONE, 2008, 3, e2473.	1,1	63
81	Nicotine Improves Cognitive Deficits of Dopamine Transporter Knockout Mice without Long-Term Tolerance. Neuropsychopharmacology, 2007, 32, 2465-2478.	2.8	47
82	Parallel Loss of Hippocampal LTD and Cognitive Flexibility in a Genetic Model of Hyperdopaminergia. Neuropsychopharmacology, 2007, 32, 2108-2116.	2.8	106
83	Loss of X-Linked Mental Retardation Gene Oligophrenin1 in Mice Impairs Spatial Memory and Leads to Ventricular Enlargement and Dendritic Spine Immaturity. Journal of Neuroscience, 2007, 27, 9439-9450.	1.7	125
84	Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease. Neurobiology of Aging, 2007, 28, 568-578.	1.5	109
85	Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice. Neuropharmacology, 2007, 52, 1496-1508.	2.0	34
86	Sustained increase of alpha7 nicotinic receptors and choline-induced improvement of learning deficit in STOP knock-out mice. Neuropharmacology, 2007, 52, 1691-1700.	2.0	24
87	Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. Neuroscience, 2007, 144, 616-622.	1.1	47
88	Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants. Neuroscience, 2007, 144, 1470-1476.	1.1	30
89	Maternal deprivation and handling modify the effect of the dopamine D3 receptor agonist, BP 897 on morphine-conditioned place preference in rats. Psychopharmacology, 2007, 193, 475-486.	1.5	32
90	P.1.g.008 Maternal deprivation and reactivity to different stress in male and female adult rats according to their estrous cycle. European Neuropsychopharmacology, 2007, 17, S307.	0.3	0

#	Article	IF	CITATIONS
91	Schizotypal dimensions: An intermediate phenotype associated with the COMT high activity allele. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 64-68.	1.1	52
92	Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Molecular Psychiatry, 2007, 12, 491-501.	4.1	124
93	Microtubule-associated STOP protein deletion triggers restricted changes in dopaminergic neurotransmission. Journal of Neurochemistry, 2007, 104, 071115085713003-???.	2.1	25
94	Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications. Biological Psychiatry, 2006, 59, 508-515.	0.7	130
95	Brief early handling increases morphine dependence in adult rats. Behavioural Brain Research, 2006, 170, 211-218.	1.2	31
96	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology, 2006, 50, 941-952.	2.0	191
97	Maternal deprivation specifically enhances vulnerability to opiate dependence. Behavioural Pharmacology, 2006, 17, 715-724.	0.8	39
98	Interaction between the vesicular glutamate transporter type 1 and endophilin A1, a protein essential for endocytosis. Journal of Neurochemistry, 2006, 97, 1111-1125.	2.1	64
99	Genome-wide scan for genes involved in bipolar affective disorder in 70 European families ascertained through a bipolar type I early-onset proband: supportive evidence for linkage at 3p14. Molecular Psychiatry, 2006, 11, 685-694.	4.1	68
100	The reinforcing effects of chronic d-amphetamine and morphine are impaired in a line of memory-deficient mice overexpressing calcineurin. European Journal of Neuroscience, 2005, 21, 3089-3096.	1.2	35
101	Maternal deprivation increases behavioural reactivity to stressful situations in adulthood: suppression by the CCK2 antagonist L365,260. Psychopharmacology, 2005, 181, 706-713.	1.5	39
102	Constitutive Hyperdopaminergia is Functionally Associated with Reduced Behavioral Lateralization. Neuropsychopharmacology, 2005, 30, 575-581.	2.8	25
103	Maternal Deprivation Increases Vulnerability to Morphine Dependence and Disturbs the Enkephalinergic System in Adulthood. Journal of Neuroscience, 2005, 25, 4453-4462.	1.7	95
104	Augmented Constitutive CREB Expression in the Nucleus accumbens and Striatum May Contribute to the Altered Behavioral Response to Cocaine of Adult Mice Exposed to Cocaine in utero. Developmental Neuroscience, 2005, 27, 235-248.	1.0	17
105	Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology, 2005, 49, 890-900.	2.0	80
106	Developmentally regulated expression of VGLUT3 during early post-natal life. Neuropharmacology, 2005, 49, 901-911.	2.0	59
107	Organic Cation Transporter 3 (Slc22a3) Is Implicated in Salt-Intake Regulation. Journal of Neuroscience, 2004, 24, 2846-2851.	1.7	97
108	Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. European Journal of Neuroscience, 2004, 20, 120-126.	1.2	70

#	Article	IF	Citations
109	Expression of vesicular glutamate transporters, VGLUT1 and VGLUT2, in cholinergic spinal motoneurons. European Journal of Neuroscience, 2004, 20, 1752-1760.	1.2	78
110	Altered neurotensin mrna expression in mice lacking the dopamine transporter. Neuroscience, 2004, 123, 537-546.	1.1	7
111	Localization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain. Neuroscience, 2004, 123, 983-1002.	1.1	225
112	Genetic Markers in Psychiatric Genetics. , 2003, 77, 63-98.		2
113	Altered cocaine-induced behavioral sensitization in adult mice exposed to cocaine in utero. Developmental Brain Research, 2003, 147, 97-105.	2.1	42
114	Lysosomal amino acid transporter LYAAT-1 in the rat central nervous system: An in situ hybridization and immunohistochemical study. Journal of Comparative Neurology, 2003, 462, 71-89.	0.9	34
115	Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nature Genetics, 2003, 34, 27-29.	9.4	1,612
116	Linkage and association of the glutamate receptor 6 gene with autism. Molecular Psychiatry, 2002, 7, 302-310.	4.1	279
117	A Third Vesicular Glutamate Transporter Expressed by Cholinergic and Serotoninergic Neurons. Journal of Neuroscience, 2002, 22, 5442-5451.	1.7	571
118	Serotonin transporter gene polymorphisms and hyperserotonemia in autistic disorder. Molecular Psychiatry, 2002, 7, 67-71.	4.1	55
119	Cocaine and Amphetamine Increase Extracellular Dopamine in the Nucleus Accumbens of Mice Lacking the Dopamine Transporter Gene. Journal of Neuroscience, 2001, 21, RC141-RC141.	1.7	187
120	The Existence of a Second Vesicular Glutamate Transporter Specifies Subpopulations of Glutamatergic Neurons. Journal of Neuroscience, 2001, 21, RC181-RC181.	1.7	530
121	Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology, 2001, 159, 2-9.	1.5	88
122	Involvement of the NH2 terminal domain of catecholamine transporters in the Na+ and Clâ^' -dependence of a [3 H]-dopamine uptake. British Journal of Pharmacology, 2001, 133, 387-394.	2.7	5
123	The NH ₂ -terminus of Norepinephrine Transporter Contains a Basolateral Localization Signal for Epithelial Cells. Molecular Biology of the Cell, 2001, 12, 3797-3807.	0.9	36
124	Determination of Residues in the Norepinephrine Transporter That Are Critical for Tricyclic Antidepressant Affinity. Journal of Biological Chemistry, 2001, 276, 8254-8260.	1.6	47
125	Identification and characterization of a lysosomal transporter for small neutral amino acids. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7206-7211.	3.3	208
126	A $Na(+)/Cl(-)$ -dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka (Oryzias latipes). Molecular Pharmacology, 2001, 60, 462-73.	1.0	20

#	Article	IF	CITATIONS
127	Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behavioural Pharmacology, 2000, 11, 279-290.	0.8	210
128	Increased rewarding properties of morphine in dopamine-transporter knockout mice. European Journal of Neuroscience, 2000, 12, 1827-1837.	1.2	75
129	Structural Domains of Chimeric Dopamine-Noradrenaline Human Transporters Involved in the Na+-and Clâ^'-Dependence of Dopamine Transport. Molecular Pharmacology, 2000, 58, 1404-1411.	1.0	18
130	Dopamine tone regulates D1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1879-1884.	3.3	88
131	Ontogeny of Rxt1, a vesicular "orphan―Na+/Clâ^'-dependent transporter, in the rat. Neuroscience, 2000, 96, 627-637.	1.1	3
132	Selective increase of Nurr1 mRNA expression in mesencephalic dopaminergic neurons of D2 dopamine receptor-deficient mice. Molecular Brain Research, 2000, 80, 1-6.	2.5	18
133	Unexpected localization of the Na+/Cldependent-like orphan transporter, Rxt1, on synaptic vesicles in the rat central nervous system. European Journal of Neuroscience, 1999, 11, 1349-1361.	1.2	35
134	Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. European Journal of Neuroscience, 1999, 11, 3499-3511.	1.2	121
135	The human desipramineâ€sensitive noradrenaline transporter and the importance of defined amino acids for its function. Autonomic and Autacoid Pharmacology, 1999, 19, 327-333.	0.7	16
136	Characterization and distribution of Hxt1, a Na+/Clâ^·dependent orphan transporter, in the human brain., 1999, 56, 146-159.		8
137	Cocaine self-administration in dopamine-transporter knockout mice. Nature Neuroscience, 1998, 1, 132-137.	7.1	463
138	Up- and down-expression of the dopamine transporter by plasmid DNA transfer in the rat brain. European Journal of Neuroscience, 1998, 10, 3607-3616.	1.2	32
139	Control of Myocardial Contractile Function by the Level of \hat{I}^2 -Adrenergic Receptor Kinase 1 in Gene-targeted Mice. Journal of Biological Chemistry, 1998, 273, 18180-18184.	1.6	153
140	Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 4029-4034.	3.3	623
141	Plasma Membrane Transporters of Serotonin, Dopamine, and Norepinephrine Mediate Serotonin Accumulation in Atypical Locations in the Developing Brain of Monoamine Oxidase A Knock-Outs. Journal of Neuroscience, 1998, 18, 6914-6927.	1.7	158
142	Les kinases couplées aux protéines G : désensibilisation des récepteurs β-adrénergiques et régulatic l'activité cardiaque Medecine/Sciences, 1998, 14, 210.	on de O.O	2
143	Cloning, gene structure and genomic localization of an orphan transporter from mouse kidney with six alternatively-spliced isoforms. Receptors and Channels, 1998, 6, 113-28.	1.1	13
144	Inactivation of the Dopamine Transporter Reveals Essential Roles of Dopamine in the Control of Locomotion, Psychostimulant Response, and Pituitary Function. Advances in Pharmacology, 1997, 42, 179-182.	1.2	15

#	Article	IF	CITATIONS
145	Anterior Pituitary Hypoplasia and Dwarfism in Mice Lacking the Dopamine Transporter. Neuron, 1997, 19, 127-138.	3.8	192
146	Cloning of a functional vesicular GABA and glycine transporter by screening of genome databases. FEBS Letters, 1997, 417, 177-183.	1.3	269
147	The dopamine transporter: A crucial component regulating dopamine transmission. Movement Disorders, 1997, 12, 629-633.	2.2	207
148	Molecular anatomy of the development of the human substantia nigra., 1997, 379, 72-87.		34
149	Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Receptors and Channels, 1997, 5, 193-9.	1.1	46
150	Essential role of \hat{A} -adrenergic receptor kinase 1 in cardiac development and function. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12974-12979.	3.3	321
151	Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 1996, 379, 606-612.	13.7	2,267
152	Le transporteur neuronal de la dopamine : de la protéine à la fonction Medecine/Sciences, 1996, 12, 1125.	0.0	0
153	The dopamine transporter. The cloned target site of parkinsonism-inducing toxins and of drugs of abuse. Advances in Neurology, 1996, 69, 235-8.	0.8	8
154	Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter. Journal of Pharmacology and Experimental Therapeutics, 1996, 277, 1437-43.	1.3	51
155	The two orphan Na+/Cl(-)-dependent transporters Rxt1 and V-7-3-2 have an overlapping expression pattern in the rat central nervous system. Receptors and Channels, 1996, 4, 227-42.	1.1	7
156	Immunolabeling of the Na+/Clâ^'dependent "orphan―transporter Rxt1 in the rat central nervous system. Journal of Neuroscience Research, 1995, 42, 423-432.	1.3	17
157	Chromosomal localization of opioid peptide and receptor genes in the mouse. Life Sciences, 1995, 56, PL369-PL375.	2.0	40
158	Glycine receptor β–subunit gene mutation in spastic mouse associated with LINE–1 element insertion. Nature Genetics, 1994, 7, 136-142.	9.4	217
159	No association between alleles or genotypes at the dopamine transporter gene and schizophrenia. Psychiatry Research, 1994, 52, 17-23.	1.7	29
160	Failure to find evidence for linkage or association between the dopamine D3 receptor gene and schizophrenia. American Journal of Psychiatry, 1994, 151, 107-111.	4.0	46
161	Characterization of an Atypical Member of the Na ⁺ Cl ^{â^'} â€Dependent Transporter Family: Chromosomal Localization and Distribution in GABAergic and Glutamatergic Neurons in the Rat Brain. Journal of Neurochemistry, 1994, 62, 445-455.	2.1	42
162	Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters Journal of Biological Chemistry, 1994, 269, 15985-15988.	1.6	258

#	Article	IF	CITATIONS
163	Cloning, pharmacological characterization, and genomic localization of the human creatine transporter. Receptors and Channels, 1994, 2, 165-74.	1.1	48
164	cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-I. Journal of Biological Chemistry, 1994, 269, 3175-80.	1.6	73
165	Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Molecular Pharmacology, 1994, 45, 608-17.	1.0	127
166	Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. Journal of Biological Chemistry, 1994, 269, 15985-8.	1.6	207
167	Molecular characterization of the dopamine transporter. Trends in Pharmacological Sciences, 1993, 14, 43-49.	4.0	503
168	VNTR polymorphism for the human dopamine transporter gene (DAT1). Human Molecular Genetics, 1993, 2, 335-335.	1.4	35
169	Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. Journal of Neuroscience, 1993, 13, 4246-4253.	1.7	173
170	Human Dopamine Transporter Gene Not Linked to Schizophrenia in Multigenerational Pedigrees. Human Heredity, 1993, 43, 319-322.	0.4	35
171	The Third Dopamine Receptor (D3): New Perspectives in Therapeutics. , 1993, 10, 82-93.		1
172	Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 8155-8159.	3.3	597
173	Molecular cloning, pharmacological characterization and genetic studies of the human dopamine transporter. European Neuropsychopharmacology, 1992, 2, 268-269.	0.3	2
174	Heterogeneity and regulation of central dopamine receptor subtypes studied by cDNA cloning methodology. Neurochemistry International, 1992, 20, 27-32.	1.9	5
175	The third dopamine receptor (D3) as a novel target for antipsychotics. Biochemical Pharmacology, 1992, 43, 659-666.	2.0	185
176	Effects of Dopaminergic Transmission Interruption on the D2Receptor Isoforms in Various Cerebral Tissues. Journal of Neurochemistry, 1992, 58, 673-679.	2.1	51
177	Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. European Journal of Pharmacology, 1992, 225, 331-337.	2.7	382
178	The dopamine receptor family: molecular biology and pharmacology. Seminars in Neuroscience, 1992, 4, 99-108.	2.3	113
179	Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Molecular Pharmacology, 1992, 42, 383-90.	1.0	339
180	Localization and function of the D3 dopamine receptor. Arzneimittelforschung, 1992, 42, 224-30.	0.5	66

#	Article	IF	CITATIONS
181	The dopamine D3 receptor as a novel target for antipsychotics. European Neuropsychopharmacology, 1991, 1, 197-199.	0.3	O
182	Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing. Biochemical and Biophysical Research Communications, 1991, 176, 1584-1592.	1.0	118
183	Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Letters, 1991, 295, 149-154.	1.3	302
184	Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Research, 1991, 564, 203-219.	1.1	825
185	Dopamine activation of the arachidonic acid cascade as a basis for D1D2 receptor synergism. Nature, 1991, 353, 164-167.	13.7	279
186	Chromosomal localization of the human D3 dopamine receptor gene. Human Genetics, 1991, 87, 618-620.	1.8	85
187	The Third Dopamine Receptor (D3) as an Autoreceptor. , 1991, , 51-54.		1
188	Cinq récepteurs pour la dopamine : mais où s'arrêteront-ils ?. Medecine/Sciences, 1991, 7, 609.	0.0	0
189	A Novel Potential Metallopeptidase Derived from the Enkephalinase Gene by Alternative Splicing. Journal of Neurochemistry, 1990, 55, 2146-2148.	2.1	20
190	Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 1990, 347, 146-151.	13.7	2,565
191	Enkephalin biosynthesis and release in mouse striatum are inhibited by GABA receptor stimulation: compared changes in preproenkephalin mRNA and Tyr-Gly-Gly levels. Molecular Brain Research, 1990, 8, 227-233.	2.5	24
192	Two D2 dopamine receptor isoforms generated via alternative mRNA splicing: regional distribution and effects of haloperidol treatments. European Journal of Pharmacology, 1990, 183, 1619.	1.7	6
193	Le troisi $ ilde{A}$ me r $ ilde{A}$ ©cepteur de la dopamine. Une nouvelle cible d'action des neuroleptiques. Medecine/Sciences, 1990, 6, 800.	0.0	1
194	Novel agents affecting enkephalinergic and histaminergic transmissions in brain., 1990,, 218-227.		0
195	Adaptative changes in two indices of enkephalin neuron activity in mouse striatum following GABAergic stimulation. Progress in Clinical and Biological Research, 1990, 328, 203-6.	0.2	0
196	Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature, 1989, 342, 923-926.	13.7	670
197	Molecular cloning and amino acid sequence of rat kidney aminopeptidase M: A member of a super family of zinc-metallohydrolases. Biochemical and Biophysical Research Communications, 1989, 161, 236-241.	1.0	139
198	Potent inhibition of cerebral aminopeptidases by carbaphethiol, a parenterally active compound. Neuropeptides, 1988, 12, 111-118.	0.9	10

#	Article	IF	CITATIONS
199	Enantiomers of thiorphan and acetorphan: correlation between enkephalinase inhibition, protection of endogenous enkephalins and behavioral effects. Journal of Pharmacology and Experimental Therapeutics, 1987, 243, 666-73.	1.3	29
200	The endogenous tripeptide Tyr-Gly-Gly as a possible metabolite of opioid peptides in rat brain: Identification, regional distribution, effects of lesions and formation in depolarized slices. Peptides, 1986, 7, 669-677.	1.2	17
201	Ectopeptidases Responsible for the Inactivation of Enkephalins. Proceedings in Life Sciences, 1986, , 272-284.	0.5	8
202	Characterization of aminopeptidases responsible for inactivating endogenous (Met5)enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies. Molecular Pharmacology, 1986, 29, 281-7.	1.0	76
203	Enkephalin metabolism and its inhibition. Biochemical Society Transactions, 1985, 13, 47-50.	1.6	15
204	Purification of membrane-bound aminopeptidase from rat brain: Identification of aminopeptidase M. Neuropeptides, 1985, 5, 485-488.	0.9	16
205	Identification of aminopeptidase M as an enkephalin-inactivating enzyme in rat cerebral membranes. Biochemistry, 1985, 24, 2179-2185.	1.2	123
206	Linkage and association of the glutamate receptor 6 gene with autism. , 0, .		3